Cabozantinib in Progressive Medullary Thyroid Cancer

RET/PTC1-Driven Neoplastic Transformation and Proinvasive Phenotype of Human Thyrocytes Involve Met Induction and β-Catenin Nuclear Translocation

(2015) Giuliana Cassinelli et al.   NEOPLASIA

Cabozantinib for the Treatment of Advanced Medullary Thyroid Cancer

(2012) Madhavi Nagilla et al.   ADVANCES IN THERAPY

Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary Regression

(2011) Mariëtte H. W. Kappers et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

(2011) Razelle Kurzrock et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer

(2010) Elaine T. Lam et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased Expression of Vascular Endothelial Growth Factor and Its Receptors, VEGFR-1 and VEGFR-2, in Medullary Thyroid Carcinoma

(2010) Clarissa Capp et al.   THYROID

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas

(2009) M M Moura et al.   BRITISH JOURNAL OF CANCER

Rising Thyroid Cancer Incidence in the United States by Demographic and Tumor Characteristics, 1980-2005

(2009) L. Enewold et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer

(2009) Martin J. Schlumberger et al.   JOURNAL OF CLINICAL ONCOLOGY

Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association

(2009) Richard T. Kloos (Chair) et al.   THYROID

Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times

(2008) Anne Laure Giraudet et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer

(2008) Maya B Lodish et al.   Expert Review of Anticancer Therapy

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

(2008) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas

(2008) S. Dvorakova et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Prognostic Significance of SomaticRETOncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study

(2007) Rossella Elisei et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

New therapeutic approaches to treat medullary thyroid carcinoma

(2007) Martin Schlumberger et al.   Nature clinical practice. Endocrinology & metabolism